Intranasal esketamine, the s-enantiomer of ketamine, is dosed to minimize psychoactive effects and has received regulatory approval in multiple countries for unipolar treatment-resistant depression when used with conventional oral antidepressants.

Authors

• Person: Not available Organization: Frontiers in Psychiatry
  The Montreal model: an integrative biomedical-psychedelic ...

Sources

• The Montreal model: an integrative biomedical-psychedelic ... www.frontiersin.org Frontiers in Psychiatry via serper

Referenced by nodes (2)

• ketamine concept
• esketamine concept